Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
31050813
DOI
10.1002/ijc.32385
Knihovny.cz E-resources
- Keywords
- CHEK2, KAP1, VUS, breast cancer, functional assay, germline mutations, ovarian cancer,
- MeSH
- Cell Line MeSH
- Checkpoint Kinase 2 genetics MeSH
- Adult MeSH
- Genetic Predisposition to Disease MeSH
- Gene Knockout Techniques MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation, Missense MeSH
- Young Adult MeSH
- Breast Neoplasms, Male genetics MeSH
- Breast Neoplasms genetics MeSH
- Ovarian Neoplasms genetics MeSH
- Sequence Deletion MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Germ-Line Mutation * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Checkpoint Kinase 2 MeSH
- CHEK2 protein, human MeSH Browser
Germline mutations in checkpoint kinase 2 (CHEK2), a multiple cancer-predisposing gene, increase breast cancer (BC) risk; however, risk estimates differ substantially in published studies. We analyzed germline CHEK2 variants in 1,928 high-risk Czech breast/ovarian cancer (BC/OC) patients and 3,360 population-matched controls (PMCs). For a functional classification of VUS, we developed a complementation assay in human nontransformed RPE1-CHEK2-knockout cells quantifying CHK2-specific phosphorylation of endogenous protein KAP1. We identified 10 truncations in 46 (2.39%) patients and in 11 (0.33%) PMC (p = 1.1 × 10-14 ). Two types of large intragenic rearrangements (LGR) were found in 20/46 mutation carriers. Truncations significantly increased unilateral BC risk (OR = 7.94; 95%CI 3.90-17.47; p = 1.1 × 10-14 ) and were more frequent in patients with bilateral BC (4/149; 2.68%; p = 0.003), double primary BC/OC (3/79; 3.80%; p = 0.004), male BC (3/48; 6.25%; p = 8.6 × 10-4 ), but not with OC (3/354; 0.85%; p = 0.14). Additionally, we found 26 missense VUS in 88 (4.56%) patients and 131 (3.90%) PMC (p = 0.22). Using our functional assay, 11 variants identified in 15 (0.78%) patients and 6 (0.18%) PMC were scored deleterious (p = 0.002). Frequencies of functionally intermediate and neutral variants did not differ between patients and PMC. Functionally deleterious CHEK2 missense variants significantly increased BC risk (OR = 3.90; 95%CI 1.24-13.35; p = 0.009) and marginally OC risk (OR = 4.77; 95%CI 0.77-22.47; p = 0.047); however, carriers low frequency will require evaluation in larger studies. Our study highlights importance of LGR detection for CHEK2 analysis, careful consideration of ethnicity in both cases and controls for risk estimates, and demonstrates promising potential of newly developed human nontransformed cell line assay for functional CHEK2 VUS classification.
BIOCEV 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Cancer Epidemiology and Genetics Masaryk Memorial Cancer Institute Brno Czech Republic
Laboratory of Cancer Cell Biology Institute of Molecular Genetics of the ASCR Prague Czech Republic
References provided by Crossref.org
CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate
Phosphorylation of PLK3 Is Controlled by Protein Phosphatase 6
Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer
